An atlas of the human liver diurnal transcriptome and its perturbation by hepatitis C virus infection

Mukherji, A. Jühling, F. Simanjuntak, Y. Crouchet, E. Del Zompo, F. Teraoka, Y. Haller, A. Baltzinger, P. Paritala, S. Rasha, F. Fujiwara, N. Gadenne, C. Slovic, N. Oudot, M. A. Durand, S. C.
Nat Commun. 2024 Aug 29;15(1):7486. doi: 10.1038/s41467-024-51698-8.

Development of an effective single-chain variable fragment recognizing a novel epitope in the hepatitis C virus E2 protein that restricts virus entry into hepatocytes

Das, S. Behera, P. Shewale, D. J. Bodele, J. Das, S. Karande, A. A.
Arch Virol. 2024 Apr 29;169(5):112. doi: 10.1007/s00705-024-06024-4.

Downregulation of SOCS1 increases interferon-induced ISGylation during differentiation of induced-pluripotent stem cells to hepatocytes

Edwards, J. S. Delabat, S. A. Badilla, A. D. DiCaprio, R. C. Hyun, J. Burgess, R. A. Silva, T. Dykxhoorn, D. M. Chen, S. X. Wang, L. Ishida, Y. Saito, T. Thomas, E.
JHEP Rep. 2022 Sep 23;4(12):100592. doi: 10.1016/j.jhepr.2022.100592. eCollection 2022 Dec.

Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants

Yokokawa, H. Shinohara, M. Teraoka, Y. Imamura, M. Nakamura, N. Watanabe, N. Date, T. Aizaki, H. Iwamura, T. Narumi, H. Chayama, K. Wakita, T.
PLoS One. 2022 Sep 22;17(9):e0274283. doi: 10.1371/journal.pone.0274283. eCollection 2022.

ヒト肝細胞キメラマウスを利用したB型 肝炎ウイルス/D型肝炎ウイルス共感染モデル

加国 雅和
Medical Science Digest（MSD)　2021；47（14）：26－27

Bile acid dysmetabolism in the gut-microbiota-liver axis under hepatitis C virus infection

Inoue, T. Funatsu, Y. Ohnishi, M. Isogawa, M. Kawashima, K. Tanaka, M. Moriya, K. Kawaratani, H. Momoda, R. Iio, E. Nakagawa, H. Suzuki, Y. Matsuura, K. Fujiwara, K. Nakajima, A. Yoshiji, H. Nakayama, J. Tanaka, Y.

Liver Int. 2021 Aug 19. doi: 10.1111/liv.15041.

Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice

Ohya, K. Imamura, M. Teraoka, Y. Uchida, T. Fujino, H. Nakahara, T. Ono, A. Murakami, E. Yamauchi, M. Kawaoka, T. Miki, D. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Aikata, H. Ishida, Y. Tateno, C. Song, H. Miyayama, Y. Hijikata, M. Chayama, K.

Biochem Biophys Res Commun. 2021 Jun 25;559:78-83. doi: 10.1016/j.bbrc.2021.04.062. Epub 2021 Apr 29.

Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model

Dent, M. Hamorsky, K. Vausselin, T. Dubuisson, J. Miyata, Y. Morikawa, Y. Matoba, N.
Cell Mol Gastroenterol Hepatol. 2021;11(1):185-198. doi: 10.1016/j.jcmgh.2020.08.009. Epub 2020 Aug 27.

Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion

Ma, C. D. Imamura, M. Talley, D. C. Rolt, A. Xu, X. Wang, A. Q. Le, D. Uchida, T. Osawa, M. Teraoka, Y. Li, K. Hu, X. Park, S. B. Chalasani, N. Irvin, P. H. Dulcey, A. E. Southall, N. Marugan, J. J. Hu, Z. Chayama, K. Frankowski, K. J. Liang, T. J.

Nat Microbiol. 2020 Aug 31. doi: 10.1038/s41564-020-0781-2.

Species differences in liver accumulation and metabolism of nucleotide prodrug sofosbuvir

Wang, T. Babusis, D. Park, Y. Niu, C. Kim, C. Zhao, X. Lu, B. Ma, B. Muench, R. C. Sperger, D. Ray, A. S. Murakami, E.

Drug Metab Pharmacokinet. 2020 Jun;35(3):334-340. doi: 10.1016/j.dmpk.2020.04.333. Epub 2020 Apr 16.

Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection

Cheng, X. Uchida, T. Xia, Y. Umarova, R. Liu, C. J. Chen, P. J. Gaggar, A. Suri, V. Mucke, M. M. Vermehren, J. Zeuzem, S. Teraoka, Y. Osawa, M. Aikata, H. Tsuji, K. Mori, N. Hige, S. Karino, Y. Imamura, M. Chayama, K. Liang, T. J.

J Clin Invest. 2020 Mar 12. pii: 135616. doi: 10.1172/JCI135616.

Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice

Osawa, M. Uchida, T. Imamura, M. Teraoka, Y. Fujino, H. Nakahara, T. Ono, A. Murakami, E. Kawaoka, T. Miki, D. Tsuge, M. Hiramatsu, A. Abe-Chayama, H. Hayes, C. N.

J Gen Virol. 2019 Jul;100(7):1123-1131.

Humanized Mouse Models for the Study of Hepatitis C and Host Interactions

Yong, K. S. M. Her, Z. Chen, Q.

Cells. 2019 Jun 17;8(6). pii: cells8060604.

Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of HCV-infected Cells and Liver to Identify Pathways Associated With Disease Development

Lupberger, J. Croonenborghs, T. Roca Suarez, A. A. Van Renne, N. Juhling, F. Oudot, M. A. Virzi, A. Bandiera, S. Jamey, C. Meszaros, G. Brumaru, D. Mukherji, A. Durand, S. C. Heydmann, L. Verrier, E. R. El Saghire, H. Hamdane, N. Bartenschlager, R. Fereshetian, S. Ramberger, E. Sinha, R. Nabian, M. Everaert, C. Jovanovic, M. Mertins, P. Carr, S. A. Chayama, K. Dali-Youcef, N. Ricci, R. Bardeesy, N. M. Fujiwara, N. Gevaert, O. Zeisel, M. B. Hoshida, Y. Pochet, N. Baumert, T. F.

Gastroenterology. 2019 Apr 9. pii: S0016-5085(19)35670-7. doi: 10.1053/j.gastro.2019.04.003.

HCV-induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response

Hamdane, N. Juhling, F. Crouchet, E. El Saghire, H. Thumann, C. Oudot, M. A. Bandiera, S. Saviano, A. Ponsolles, C. Roca Suarez, A. A. Li, S. Fujiwara, N. Ono, A. Davidson, I. Bardeesy, N. Schmidl, C. Bock, C. Schuster, C. Lupberger, J. Habersetzer, F. Doffoel, M. Piardi, T. Sommacale, D. mamura, M. Uchida, T. Ohdan, H. Aikata, H. Chayama, K. Boldanova, T. Pessaux, P. Fuchs, B. C. Hoshida, Y. Zeisel, M. B. Duong, F. H. T. Baumert, T. F.

Gastroenterology. 2019 Mar 2. pii: S0016-5085(19)32506-5. doi: 10.1053/j.gastro.2019.02.038.

Hepatic IFN-Induced Protein with Tetratricopeptide Repeats Regulation of HCV Infection

Ishida, Y. Kakuni, M. Bang, B. R. Sugahara, G. Lau, D. T. Tateno-Mukaidani, C. Li, M. Gale, M., Jr. Saito, T.

J Interferon Cytokine Res. 2019 Mar;39(3):133-146. doi: 10.1089/jir.2018.0103.

Ribonucleotide reductase M2 promotes RNA replication of hepatitis C virus by protecting NS5B protein from hPLIC1-dependent proteasomal degradation

Kitab, B. Satoh, M. Ohmori, Y. Munakata, T. Sudoh, M. Kohara, M. Tsukiyama-Kohara, K.

J Biol Chem. 2019 Feb 12. pii: RA118.004397. doi: 10.1074/jbc.RA118.004397.

Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure

Teraoka, Y. Uchida, T. Imamura, M. Hiraga, N. Osawa, M. Kan, H. Saito, Y. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

J Gen Virol. 2018 Jun 19. doi: 10.1099/jgv.0.001091.

Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice

Teraoka, Y. Uchida, T. Imamura, M. Osawa, M. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

Biochem Biophys Res Commun. 2018 Jun 2;500(2):152-157.

Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection

Rolt, A. Le, D. Hu, Z. Wang, A. Q. Shah, P. Singleton, M. Hughes, E. Dulcey, A. E.He, S. Imamura, M. Uchida, T. Chayama, K. Xu, X. Marugan, J. J. Liang, T. J.

J Infect Dis. 2018 Jan 24. pii: 4823490. doi: 10.1093/infdis/jiy039.